# Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

> **NCT03302247** · PHASE2 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Non Small Cell Lung Cancer Stage IIIB

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Nivolumab+Gemcitabine

## Key facts

- **NCT ID:** NCT03302247
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-15
- **Primary completion:** 2019-03-21
- **Final completion:** 2019-07-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Unable to accrue subjects
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03302247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03302247, "Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03302247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*